Skip to content

Heart And Lung Failure - Pediatric INsulin Titration Trial

Heart And Lung Failure - Pediatric INsulin Titration Trial (HALF-PINT)

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01565941
Acronym
HALF-PINT
Enrollment
713
Registered
2012-03-29
Start date
2012-04-30
Completion date
2018-02-28
Last updated
2022-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Respiratory Failure

Keywords

Cardiovascular, Respiratory, Failure, Heart, Lung, Continuous glucose monitoring, Tight glycemic control, Subcutaneous, Insulin, Algorithm

Brief summary

Stress hyperglycemia, a state of abnormal metabolism with supra-normal blood glucose levels, is often seen in critically ill patients. Tight glycemic control (TGC) was originally shown to reduce morbidity and mortality in a landmark randomized clinical trial (RCT) of adult critically ill surgical patients but has since come under intense scrutiny due to conflicting results in recent adult trials. One pediatric RCT has been published to date that demonstrated survival benefit but was complicated by an unacceptably high rate of severe hypoglycemia. The Heart And Lung Failure - Pediatric INsulin Titration (HALF-PINT) trial is a multi-center, randomized clinical treatment trial comparing two ranges of glucose control in hyperglycemic critically ill children with heart and/or lung failure. Both target ranges of glucose control fall within the range of usual care for critically ill children managed in pediatric intensive care units. The purpose of the study is to determine the comparative effectiveness of tight glycemic control to a target range of 80-110 mg/dL (TGC-1, 4.4-6.1 mmol/L) vs. a target range of 150-180 mg/dL (TGC-2, 8.3-10.0 mmol/L) on hospital mortality and intensive care unit (ICU) length of stay (LOS) in hyperglycemic critically ill children with cardiovascular and/or respiratory failure. This will be accomplished using an explicit insulin titration algorithm and continuous glucose monitoring to safely achieve these glucose targets. Both groups will receive identical standardized intravenous glucose at an age-appropriate rate in order to provide basal calories and mitigate hypoglycemia. Insulin infusions will be titrated with an explicit algorithm combined with continuous glucose monitoring using a protocol that has been safely implemented in 490 critically ill infants and children.

Interventions

DRUGInsulin

IV insulin titration to target a blood glucose of 80-110 mg/dL

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
Boston Children's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
2 Weeks to 17 Years
Healthy volunteers
No

Inclusion criteria

* Cardiovascular failure and/or respiratory failure: 1. Cardiovascular Failure: Dopamine or dobutamine \> 5 mcg/kg/min, or any dose of epinephrine, norepinephrine, phenylephrine, milrinone or vasopressin if used to treat hypotension. 2. Respiratory Failure: Acute mechanical ventilation via endotracheal tube or tracheostomy. * Age \>= 2 weeks and corrected gestational age \>= 42 weeks * Age \< 18 years (has not yet had 18th birthday)

Exclusion criteria

* No longer has cardiovascular or respiratory failure (as defined in inclusion criterion 1), or is expected to be extubated in the next 24 hours * Expected to remain in ICU \< 24 hours * Previously randomized in HALF-PINT * Enrolled in a competing clinical trial * Family/team decision to limit/redirect from aggressive ICU technological support * Chronic ventilator dependence prior to ICU admission (non-invasive ventilation and ventilation via tracheostomy overnight or during sleep are acceptable) * Type 1 or 2 diabetes * Cardiac surgery within prior 2 months or during/planned for this hospitalization (extra-corporeal life support or non-cardiac surgery is acceptable) * Diffuse skin disease that does not allow securement of a subcutaneous sensor * Therapeutic plan to remain intubated for \>28 days * Receiving therapeutic cooling with targeted body temperatures \<34 degrees Celsius * Current or planned ketogenic diet * Ward of the state * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
ICU-Free DaysStudy day 2828-day hospital mortality-adjusted ICU length of stay.

Secondary

MeasureTime frameDescription
28-day Hospital Mortality28 days after randomizationWe will collect data on 28-day hospital mortality.
Accumulation of Multiple Organ Dysfunction Syndrome (MODS)28 days after randomizationAccumulation of MODS during the 28 days following randomization will be measured. MODS is defined as the concurrent dysfunction of two or more organ systems (e.g., acute lung injury and renal failure). The clinical relevance of MODS as a surrogate outcome measure is well recognized in the intensive care community, and there is a clear relationship between the number of dysfunctional organ systems and the risk of death in critically ill children.
Ventilator-Free Days28 days following randomizationVentilator-free days during the 28 days following randomization encompasses both reduction in the duration of ventilation and improvement in mortality. The end of the subject's duration of ventilation is defined as the date/time of extubation for subjects who are intubated, or the date/time of the discontinuation of mechanical ventilation for subjects with tracheostomy.
Developmental Neurobehavioral Outcomes: VABS-II CompositeOne year after ICU courseReliable, reproducible measures of adaptive functioning, behavior and quality of life will be used to determine outcomes at baseline (CBCL, PedsQL) and at one year after ICU discharge (Vineland-II, CBCL, PedsQL). The goal of baseline data collection is to assess pre-ICU health and quality of life. The results of the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) are reported. Scores range from 20-160, with higher scores being better.
Participants With Device-Related or Non-Device Related Nosocomial InfectionUp to 48 hours after ICU dischargeWe will use Centers for Disease Control's (CDC) most recently published definitions for the following nosocomial infections attributable to the ICU stay: total bloodstream infections including Central Venous Line (CVL)-associated bloodstream infections (BSI), respiratory tract infections including ventilator-associated pneumonias, urinary tract infections, and wound infections that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit.
Participants With Any Hypoglycemia (<60 mg/dL), Related to Insulin Infusion (Insulin Algorithm Safety)Participants will be followed for the duration of ICU stay, an expected average of 8 daysHypoglycemia will be tracked and reported according to three ranges: severe (\<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia \<2.5 mmol/L will also be tracked.
Incidence of Catheter-Associated Bloodstream InfectionUp to 48 hours after ICU dischargeWe will use Centers for Disease Control's (CDC) most recently published definition for the following nosocomial infection attributable to the ICU stay: Central Venous Line (CVL)-associated bloodstream infections (BSI) that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit. This device-related infection will be counted per 1,000 device days.
Incidence of Catheter-Associated Urinary Tract InfectionUp to 48 hours after ICU dischargeWe will use Centers for Disease Control's (CDC) most recently published definition for the following nosocomial infection attributable to the ICU stay: urinary tract infections that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit. This device-related infection will be counted per 1,000 device days.
Incidence of Ventilator-Associated PneumoniaUp to 48 hours after ICU dischargeWe will use Centers for Disease Control's (CDC) most recently published definition for the following nosocomial infection attributable to the ICU stay: respiratory tract infections including ventilator-associated pneumonias that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit. This device-related infection will be counted per 1,000 device days.
90-day Hospital Mortality90 days after randomizationIn order to enable direct comparisons between data gathered in HALF-PINT and the prior adult NICE-SUGAR trial, we will collect data on 90-day hospital mortality.
Participants With Severe Hypoglycemia (<40 mg/dL), Unrelated to Insulin Infusion (Insulin Algorithm Safety)Participants will be followed for the duration of ICU stay, an expected average of 8 daysHypoglycemia will be tracked and reported according to three ranges: severe (\<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia \<2.5 mmol/L will also be tracked.
Participants With Severe Hypoglycemia (<40 mg/dL), Related to Insulin Infusion (Insulin Algorithm Safety)Participants will be followed for the duration of ICU stay, an expected average of 8 daysHypoglycemia will be tracked and reported according to three ranges: severe (\<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia \<2.5 mmol/L will also be tracked.
Participants With Any Hypoglycemia (<60 mg/dL), Unrelated to Insulin Infusion (Insulin Algorithm Safety)Participants will be followed for the duration of ICU stay, an expected average of 8 daysHypoglycemia will be tracked and reported according to three ranges: severe (\<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia \<2.5 mmol/L will also be tracked.
Participants With Hypokalemia (<2.5 mmol/L)Participants will be followed for the duration of ICU stay, an expected average of 8 daysHypoglycemia will be tracked and reported according to three ranges: severe (\<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia \<2.5 mmol/L will also be tracked.
Nursing Workload: SWAT (Subjective Workload Assessment Technique) InstrumentOne nursing shift caring for patient on TGC, at anytime during the patient's hospital stay through the tenth nursing shift for the patient. Shift determined randomly by the last digit of the study ID number, 0-9 (0=shift 10, 1=shift 1, 2=shift 2, etc.).The workload burden placed upon bedside nurses when managing a patient on TGC will be described. Bedside nurses will be randomly selected to complete an anonymous survey describing their perceptions of workload burden associated with managing a patient during one shift. Using the SWAT (Subjective Workload Assessment Technique) instrument, perceived workload of Pediatric Intensive Care Nurses caring for HALF-PINT patients in TGC group 1 and TGC group 2 were assessed. The SWAT has been used to study the effect of workload in the fields of nursing, pharmacy and medicine. It measures the following burdens: cognitive (mental effort or concentration required for complexity of task), time (amount of spare time, interruptions, overlapping tasks) and psychological stress associated with work that impacts performance. The SWAT uses a ranking system to weight perceived workload which results in an overall score ranging from 0-100, where higher scores indicate higher perceived workload.
Nursing Workload: NASA-TLX (National Aeronautics and Space Administration - Task Load Index) InstrumentOne nursing shift caring for patient on TGC, at anytime during the patient's hospital stay through the tenth nursing shift for the patient. Shift determined randomly by the last digit of the study ID number, 0-9 (0=shift 10, 1=shift 1, 2=shift 2, etc.).The cognitive burden placed upon bedside nurses when managing a patient on TGC will be described. Bedside nurses will be randomly selected to complete an anonymous survey describing their perceptions of workload burden associated with managing a patient on TGC. Using the NASA-TLX instrument, perceived workload of Pediatric Intensive Care Nurses caring for HALF-PINT patients in TGC group 1 and TGC group 2 were assessed. The instrument uses a ranking system to weight perceived workload which results in an overall sore ranging from 0-100, where higher scores indicate higher perceived workload. It obtains overall perception of workload related to stressful tasks and includes 6 dimensions (cognitive demand, physical demand, time pressure, performance, effort, and frustration.
Insulin Algorithm Performance: Time to the Target RangeUntil study discharge, up to 28 days following randomizationPerformance of the algorithm across diverse ages, weights and disease processes will be critical to measure and compare to other published algorithm performance. Ideally, the algorithm will minimize time to glucose target range. We will track the overall glycemic profile using time-weighted glucose average because it is uniquely unaffected by the increased frequency of BG determinations that occur when glucose is abnormally low or high.
Insulin Algorithm Performance: Time in the Target RangeUntil study discharge, up to 28 days following randomizationPerformance of the algorithm across diverse ages, weights and disease processes will be critical to measure and compare to other published algorithm performance. Ideally, the algorithm will maximize time spent in the glucose target range. We will track the overall glycemic profile using time-weighted glucose average because it is uniquely unaffected by the increased frequency of BG determinations that occur when glucose is abnormally low or high.
Insulin Algorithm Performance: Time-Weighted Glucose AverageUntil study discharge, up to 28 days following randomizationPerformance of the algorithm across diverse ages, weights and disease processes will be critical to measure and compare to other published algorithm performance. We will track the overall glycemic profile using time-weighted glucose average because it is uniquely unaffected by the increased frequency of BG determinations that occur when glucose is abnormally low or high.
Incidence of Wound Infection Incidence of Wound InfectionUp to 48 hours after ICU dischargeWe will use Centers for Disease Control's (CDC) most recently published definition for the following nosocomial infection attributable to the ICU stay: wound infections that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit. This non-device-related infection will be counted per 1,000 ICU days.

Countries

Australia, Canada, United States

Participant flow

Participants by arm

ArmCount
Tight Glycemic Control 1 (TGC-1)
Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 80-110 mg/dL
349
Tight Glycemic Control 2 (TGC-2)
Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 150-180 mg/dL
349
Total698

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyRandomized; did not receive intevention82
Overall StudyWithdrawn by parent/guardian32

Baseline characteristics

CharacteristicTight Glycemic Control 1 (TGC-1)Tight Glycemic Control 2 (TGC-2)Total
Age, Categorical
<=18 years
349 Participants349 Participants698 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants0 Participants0 Participants
Age, Continuous5.5 Years6.7 Years6.2 Years
Region of Enrollment
Canada
1 participants1 participants2 participants
Region of Enrollment
United States
348 participants348 participants696 participants
Sex: Female, Male
Female
164 Participants169 Participants333 Participants
Sex: Female, Male
Male
185 Participants180 Participants365 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
122 / 349112 / 349
serious
Total, serious adverse events
18 / 3497 / 349

Outcome results

Primary

ICU-Free Days

28-day hospital mortality-adjusted ICU length of stay.

Time frame: Study day 28

ArmMeasureValue (MEDIAN)
Tight Glycemic Control 1 (TGC-1)ICU-Free Days20 Days
Tight Glycemic Control 2 (TGC-2)ICU-Free Days19.4 Days
Secondary

28-day Hospital Mortality

We will collect data on 28-day hospital mortality.

Time frame: 28 days after randomization

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Tight Glycemic Control 1 (TGC-1)28-day Hospital Mortality47 Participants
Tight Glycemic Control 2 (TGC-2)28-day Hospital Mortality32 Participants
Secondary

90-day Hospital Mortality

In order to enable direct comparisons between data gathered in HALF-PINT and the prior adult NICE-SUGAR trial, we will collect data on 90-day hospital mortality.

Time frame: 90 days after randomization

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Tight Glycemic Control 1 (TGC-1)90-day Hospital Mortality52 Participants
Tight Glycemic Control 2 (TGC-2)90-day Hospital Mortality40 Participants
Secondary

Accumulation of Multiple Organ Dysfunction Syndrome (MODS)

Accumulation of MODS during the 28 days following randomization will be measured. MODS is defined as the concurrent dysfunction of two or more organ systems (e.g., acute lung injury and renal failure). The clinical relevance of MODS as a surrogate outcome measure is well recognized in the intensive care community, and there is a clear relationship between the number of dysfunctional organ systems and the risk of death in critically ill children.

Time frame: 28 days after randomization

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Tight Glycemic Control 1 (TGC-1)Accumulation of Multiple Organ Dysfunction Syndrome (MODS)326 Participants
Tight Glycemic Control 2 (TGC-2)Accumulation of Multiple Organ Dysfunction Syndrome (MODS)324 Participants
Secondary

Developmental Neurobehavioral Outcomes: VABS-II Composite

Reliable, reproducible measures of adaptive functioning, behavior and quality of life will be used to determine outcomes at baseline (CBCL, PedsQL) and at one year after ICU discharge (Vineland-II, CBCL, PedsQL). The goal of baseline data collection is to assess pre-ICU health and quality of life. The results of the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) are reported. Scores range from 20-160, with higher scores being better.

Time frame: One year after ICU course

ArmMeasureValue (MEAN)Dispersion
Tight Glycemic Control 1 (TGC-1)Developmental Neurobehavioral Outcomes: VABS-II Composite79.9 Score on a scaleStandard Deviation 25.5
Tight Glycemic Control 2 (TGC-2)Developmental Neurobehavioral Outcomes: VABS-II Composite79.4 Score on a scaleStandard Deviation 26.9
Secondary

Incidence of Catheter-Associated Bloodstream Infection

We will use Centers for Disease Control's (CDC) most recently published definition for the following nosocomial infection attributable to the ICU stay: Central Venous Line (CVL)-associated bloodstream infections (BSI) that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit. This device-related infection will be counted per 1,000 device days.

Time frame: Up to 48 hours after ICU discharge

ArmMeasureValue (NUMBER)
Tight Glycemic Control 1 (TGC-1)Incidence of Catheter-Associated Bloodstream Infection1.94 Infections/1000 CVC days
Tight Glycemic Control 2 (TGC-2)Incidence of Catheter-Associated Bloodstream Infection0 Infections/1000 CVC days
Secondary

Incidence of Catheter-Associated Urinary Tract Infection

We will use Centers for Disease Control's (CDC) most recently published definition for the following nosocomial infection attributable to the ICU stay: urinary tract infections that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit. This device-related infection will be counted per 1,000 device days.

Time frame: Up to 48 hours after ICU discharge

ArmMeasureValue (NUMBER)
Tight Glycemic Control 1 (TGC-1)Incidence of Catheter-Associated Urinary Tract Infection2.19 Infections/1000 bladder catheter days
Tight Glycemic Control 2 (TGC-2)Incidence of Catheter-Associated Urinary Tract Infection1.79 Infections/1000 bladder catheter days
Secondary

Incidence of Ventilator-Associated Pneumonia

We will use Centers for Disease Control's (CDC) most recently published definition for the following nosocomial infection attributable to the ICU stay: respiratory tract infections including ventilator-associated pneumonias that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit. This device-related infection will be counted per 1,000 device days.

Time frame: Up to 48 hours after ICU discharge

ArmMeasureValue (NUMBER)
Tight Glycemic Control 1 (TGC-1)Incidence of Ventilator-Associated Pneumonia0.94 Infections/1000 ventilator days
Tight Glycemic Control 2 (TGC-2)Incidence of Ventilator-Associated Pneumonia0 Infections/1000 ventilator days
Secondary

Incidence of Wound Infection Incidence of Wound Infection

We will use Centers for Disease Control's (CDC) most recently published definition for the following nosocomial infection attributable to the ICU stay: wound infections that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit. This non-device-related infection will be counted per 1,000 ICU days.

Time frame: Up to 48 hours after ICU discharge

ArmMeasureValue (NUMBER)
Tight Glycemic Control 1 (TGC-1)Incidence of Wound Infection Incidence of Wound Infection0 Infections/1000 ICU days
Tight Glycemic Control 2 (TGC-2)Incidence of Wound Infection Incidence of Wound Infection0 Infections/1000 ICU days
Secondary

Insulin Algorithm Performance: Time in the Target Range

Performance of the algorithm across diverse ages, weights and disease processes will be critical to measure and compare to other published algorithm performance. Ideally, the algorithm will maximize time spent in the glucose target range. We will track the overall glycemic profile using time-weighted glucose average because it is uniquely unaffected by the increased frequency of BG determinations that occur when glucose is abnormally low or high.

Time frame: Until study discharge, up to 28 days following randomization

ArmMeasureValue (MEDIAN)
Tight Glycemic Control 1 (TGC-1)Insulin Algorithm Performance: Time in the Target Range57 Percentage of time
Tight Glycemic Control 2 (TGC-2)Insulin Algorithm Performance: Time in the Target Range91 Percentage of time
Secondary

Insulin Algorithm Performance: Time to the Target Range

Performance of the algorithm across diverse ages, weights and disease processes will be critical to measure and compare to other published algorithm performance. Ideally, the algorithm will minimize time to glucose target range. We will track the overall glycemic profile using time-weighted glucose average because it is uniquely unaffected by the increased frequency of BG determinations that occur when glucose is abnormally low or high.

Time frame: Until study discharge, up to 28 days following randomization

ArmMeasureValue (MEDIAN)
Tight Glycemic Control 1 (TGC-1)Insulin Algorithm Performance: Time to the Target Range5.5 Hours
Tight Glycemic Control 2 (TGC-2)Insulin Algorithm Performance: Time to the Target Range1.5 Hours
Secondary

Insulin Algorithm Performance: Time-Weighted Glucose Average

Performance of the algorithm across diverse ages, weights and disease processes will be critical to measure and compare to other published algorithm performance. We will track the overall glycemic profile using time-weighted glucose average because it is uniquely unaffected by the increased frequency of BG determinations that occur when glucose is abnormally low or high.

Time frame: Until study discharge, up to 28 days following randomization

ArmMeasureValue (MEDIAN)
Tight Glycemic Control 1 (TGC-1)Insulin Algorithm Performance: Time-Weighted Glucose Average109 mg/dL
Tight Glycemic Control 2 (TGC-2)Insulin Algorithm Performance: Time-Weighted Glucose Average123 mg/dL
Secondary

Nursing Workload: NASA-TLX (National Aeronautics and Space Administration - Task Load Index) Instrument

The cognitive burden placed upon bedside nurses when managing a patient on TGC will be described. Bedside nurses will be randomly selected to complete an anonymous survey describing their perceptions of workload burden associated with managing a patient on TGC. Using the NASA-TLX instrument, perceived workload of Pediatric Intensive Care Nurses caring for HALF-PINT patients in TGC group 1 and TGC group 2 were assessed. The instrument uses a ranking system to weight perceived workload which results in an overall sore ranging from 0-100, where higher scores indicate higher perceived workload. It obtains overall perception of workload related to stressful tasks and includes 6 dimensions (cognitive demand, physical demand, time pressure, performance, effort, and frustration.

Time frame: One nursing shift caring for patient on TGC, at anytime during the patient's hospital stay through the tenth nursing shift for the patient. Shift determined randomly by the last digit of the study ID number, 0-9 (0=shift 10, 1=shift 1, 2=shift 2, etc.).

ArmMeasureValue (MEDIAN)
Tight Glycemic Control 1 (TGC-1)Nursing Workload: NASA-TLX (National Aeronautics and Space Administration - Task Load Index) Instrument35.0 score on a scale
Tight Glycemic Control 2 (TGC-2)Nursing Workload: NASA-TLX (National Aeronautics and Space Administration - Task Load Index) Instrument20.4 score on a scale
Secondary

Nursing Workload: SWAT (Subjective Workload Assessment Technique) Instrument

The workload burden placed upon bedside nurses when managing a patient on TGC will be described. Bedside nurses will be randomly selected to complete an anonymous survey describing their perceptions of workload burden associated with managing a patient during one shift. Using the SWAT (Subjective Workload Assessment Technique) instrument, perceived workload of Pediatric Intensive Care Nurses caring for HALF-PINT patients in TGC group 1 and TGC group 2 were assessed. The SWAT has been used to study the effect of workload in the fields of nursing, pharmacy and medicine. It measures the following burdens: cognitive (mental effort or concentration required for complexity of task), time (amount of spare time, interruptions, overlapping tasks) and psychological stress associated with work that impacts performance. The SWAT uses a ranking system to weight perceived workload which results in an overall score ranging from 0-100, where higher scores indicate higher perceived workload.

Time frame: One nursing shift caring for patient on TGC, at anytime during the patient's hospital stay through the tenth nursing shift for the patient. Shift determined randomly by the last digit of the study ID number, 0-9 (0=shift 10, 1=shift 1, 2=shift 2, etc.).

ArmMeasureValue (MEDIAN)
Tight Glycemic Control 1 (TGC-1)Nursing Workload: SWAT (Subjective Workload Assessment Technique) Instrument50.0 score on a scale
Tight Glycemic Control 2 (TGC-2)Nursing Workload: SWAT (Subjective Workload Assessment Technique) Instrument36.2 score on a scale
Secondary

Participants With Any Hypoglycemia (<60 mg/dL), Related to Insulin Infusion (Insulin Algorithm Safety)

Hypoglycemia will be tracked and reported according to three ranges: severe (\<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia \<2.5 mmol/L will also be tracked.

Time frame: Participants will be followed for the duration of ICU stay, an expected average of 8 days

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Tight Glycemic Control 1 (TGC-1)Participants With Any Hypoglycemia (<60 mg/dL), Related to Insulin Infusion (Insulin Algorithm Safety)64 Participants
Tight Glycemic Control 2 (TGC-2)Participants With Any Hypoglycemia (<60 mg/dL), Related to Insulin Infusion (Insulin Algorithm Safety)5 Participants
Secondary

Participants With Any Hypoglycemia (<60 mg/dL), Unrelated to Insulin Infusion (Insulin Algorithm Safety)

Hypoglycemia will be tracked and reported according to three ranges: severe (\<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia \<2.5 mmol/L will also be tracked.

Time frame: Participants will be followed for the duration of ICU stay, an expected average of 8 days

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Tight Glycemic Control 1 (TGC-1)Participants With Any Hypoglycemia (<60 mg/dL), Unrelated to Insulin Infusion (Insulin Algorithm Safety)26 Participants
Tight Glycemic Control 2 (TGC-2)Participants With Any Hypoglycemia (<60 mg/dL), Unrelated to Insulin Infusion (Insulin Algorithm Safety)29 Participants
Secondary

Participants With Device-Related or Non-Device Related Nosocomial Infection

We will use Centers for Disease Control's (CDC) most recently published definitions for the following nosocomial infections attributable to the ICU stay: total bloodstream infections including Central Venous Line (CVL)-associated bloodstream infections (BSI), respiratory tract infections including ventilator-associated pneumonias, urinary tract infections, and wound infections that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit.

Time frame: Up to 48 hours after ICU discharge

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Tight Glycemic Control 1 (TGC-1)Participants With Device-Related or Non-Device Related Nosocomial Infection12 Participants
Tight Glycemic Control 2 (TGC-2)Participants With Device-Related or Non-Device Related Nosocomial Infection4 Participants
Secondary

Participants With Hypokalemia (<2.5 mmol/L)

Hypoglycemia will be tracked and reported according to three ranges: severe (\<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia \<2.5 mmol/L will also be tracked.

Time frame: Participants will be followed for the duration of ICU stay, an expected average of 8 days

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Tight Glycemic Control 1 (TGC-1)Participants With Hypokalemia (<2.5 mmol/L)76 Participants
Tight Glycemic Control 2 (TGC-2)Participants With Hypokalemia (<2.5 mmol/L)64 Participants
Secondary

Participants With Severe Hypoglycemia (<40 mg/dL), Related to Insulin Infusion (Insulin Algorithm Safety)

Hypoglycemia will be tracked and reported according to three ranges: severe (\<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia \<2.5 mmol/L will also be tracked.

Time frame: Participants will be followed for the duration of ICU stay, an expected average of 8 days

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Tight Glycemic Control 1 (TGC-1)Participants With Severe Hypoglycemia (<40 mg/dL), Related to Insulin Infusion (Insulin Algorithm Safety)13 Participants
Tight Glycemic Control 2 (TGC-2)Participants With Severe Hypoglycemia (<40 mg/dL), Related to Insulin Infusion (Insulin Algorithm Safety)1 Participants
Secondary

Participants With Severe Hypoglycemia (<40 mg/dL), Unrelated to Insulin Infusion (Insulin Algorithm Safety)

Hypoglycemia will be tracked and reported according to three ranges: severe (\<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia \<2.5 mmol/L will also be tracked.

Time frame: Participants will be followed for the duration of ICU stay, an expected average of 8 days

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Tight Glycemic Control 1 (TGC-1)Participants With Severe Hypoglycemia (<40 mg/dL), Unrelated to Insulin Infusion (Insulin Algorithm Safety)5 Participants
Tight Glycemic Control 2 (TGC-2)Participants With Severe Hypoglycemia (<40 mg/dL), Unrelated to Insulin Infusion (Insulin Algorithm Safety)6 Participants
Secondary

Ventilator-Free Days

Ventilator-free days during the 28 days following randomization encompasses both reduction in the duration of ventilation and improvement in mortality. The end of the subject's duration of ventilation is defined as the date/time of extubation for subjects who are intubated, or the date/time of the discontinuation of mechanical ventilation for subjects with tracheostomy.

Time frame: 28 days following randomization

ArmMeasureValue (MEDIAN)
Tight Glycemic Control 1 (TGC-1)Ventilator-Free Days21.8 Days
Tight Glycemic Control 2 (TGC-2)Ventilator-Free Days20.9 Days

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026